Sarm1 enzyme activity inhibitor and application thereof
US-2024368168-A1 · Nov 7, 2024 · US
Polyethylene glycol based prodrug of adrenomedullin and use thereof
US10035818B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10035818-B2 |
| Application number | US-201715472476-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 29, 2017 |
| Priority date | Nov 3, 2011 |
| Publication date | Jul 31, 2018 |
| Grant date | Jul 31, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to novel polyethylene glycol (PEG) based prodrug of Adrenomedullin, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for producing medicaments for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound of the formula (IV) wherein n represents 0, 1, 2, or 3; and R 1 represents hydrogen, methyl, ethyl, n-propyl or isopropyl. 2. The compound of claim 1 wherein n represents 1 or 2; and R 1 is hydrogen or methyl. 3. The compound of claim 1 wherein the is a compound of formula (III)
Assignees
Inventors
Classifications
Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695) · CPC title
and aromatic or cycloaliphatic · CPC title
- C07K5/06017Primary
and aliphatic · CPC title
containing at least one abnormal peptide link · CPC title
- A61K47/60Primary
the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10035818B2 cover?
- The invention relates to novel polyethylene glycol (PEG) based prodrug of Adrenomedullin, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for producing medicaments for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders.
- Who is the assignee on this patent?
- Bayer Pharma AG, Bayer Ip Gmbh
- What technology area does this patent fall under?
- Primary CPC classification C07K5/06017. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).